Rett Syndrome astrocytes disrupt neuronal activity and cerebral organoid development through transfer of dysfunctional mitochondria

Abstract

Studies on the function of Methyl CpG binding protein 2 (MECP2) and the consequence of MECP2 deficiency and duplication have largely focused on neurons. The function of MECP2 in human glia, along with the comprehensive understanding of glial function in neurodevelopmental disorders, is much less understood. Using female and male human embryonic stem cell (hESC) lines to model MECP2 loss-of-function (LOF) in Rett Syndrome (RTT) in the developing brain, we investigated the molecular underpinnings of astrocyte (AST) development and dysfunction, and the mechanisms by which AST contribute to neuronal activity. Here we show that hESC-derived RTT ASTs have fewer mitochondria yet similar levels of reactive oxygen species compared to isogenic controls (CTR). We identified significantly diminished mitochondrial respiration that was compensated by increased glycolysis, and that the molecular mechanism behind mitochondrial dysfunction were reduced key proteins around the tricarboxylic acid (TCA) cycle and electron transport chain (ETC). We found an increased abundance of cytosolic amino acids in RTT ASTs under basal conditions that was readily depleted when energy demands were increased. We determined that RTT AST can donate their mitochondria to hESC-derived cortical neurons, and that isolated mitochondria from RTT ASTs are sufficient to cause significant changes to neuronal activity, increasing local field potentials to a hyperexcitable state. To examine mitochondrial health in the developing brain, we derived cerebral organoids. Ultrastructural analysis indicated that mitochondria from RTT hESC-derived organoids were significantly smaller compared to mitochondria from CTR organoids, indicating decreased connectivity and function, and this phenotype was stronger in glia compared to neurons. Using a multiomics epigenetics approach, we found hallmarks of RTT developmental delay and glial specific gene expression changes that corroborate altered energy metabolism and mitochondrial dysfunction. Based on these results, we propose that release of dysfunctional mitochondria from RTT ASTs to neurons furthers pathophysiology of the syndrome.